10-Q: Encompass Health Q3 revenue up 9.4%

Encompass Health delivered double‑digit year‑to‑date growth, expanded capacity, redeemed 2025 notes, and flagged a 2.9% Medicare rate lift effective October 1 while noting ongoing RCD audit risk.

Summary

• Net operating revenues rose 9.4% to $1,477.5m in Q3 2025 (9M: up 10.6% to $4,390.6m).
• Income from continuing operations increased 18.4% to $175.0m in Q3 (9M: $557.8m, +28.1%).
• Net income attributable to Encompass Health was $126.5m in Q3 (9M: $420.1m).
• Diluted EPS from continuing operations was $1.24 in Q3 (9M: $4.13).
• Adjusted EBITDA was $300.1m in Q3 (9M: $932.3m).
• Discharges grew 5.0% to 65,839; net patient revenue per discharge up 3.3% to $21,679; occupancy 76.2%.
• Q3 payor mix: Medicare 64.1%, Medicare Advantage 16.6%, Managed Care 11.1%; Medicaid supplemental payments boosted 'other' revenue.
• Cash from operations (9M) was $829.6m; capex (9M) $507.1m with 2025 capex plan of $785–$820m.
• Debt: Long-term debt net of current portion $2,393.9m; redeemed remaining $100m 5.75% notes due 2025 in September; ~$873m revolver availability.
• 2026 IRF Final Rule implies ~2.9% Medicare payment rate increase for the company effective 2025-10-01.
• OBBBA expected to add ~$180m of 2025 deductions and deliver ~$50m cash tax savings; estimated 2025 cash taxes $110–$130m.
• Continued de novo expansion: new hospitals opened in Athens (Mar), Fort Myers (May), Daytona Beach (Jul), and Danbury (Sep); bed additions including a Wildwood, FL satellite.

Sentiment

Score: 7

Explanation: Solid growth, margins, and cash generation; favorable Medicare update and tax tailwind, offset by elevated capex and RCD audit risk.

Positives

• Strong top-line growth: Q3 revenue +9.4% to $1,477.5m; 9M +10.6% to $4,390.6m.
• Operating leverage: Q3 operating expenses 83.5% of revenue (improved vs. 84.5% LY); salaries and benefits down to 53.1% of revenue.
• Adjusted EBITDA of $300.1m in Q3 (9M $932.3m), reflecting volume growth and pricing.
• Discharge growth of 5.0% with net patient revenue per discharge up 3.3%; occupancy improved to 76.2%.
• Labor pressures easing: contract labor FTEs down 17.7% YoY; EPOB stable.
• Balance sheet flexibility: no significant debt maturities until 2028; ~$873m revolver availability; redeemed $100m 2025 notes.
• Shareholder returns: $0.19 quarterly dividend declared (payable 2026-01-15) and $81.7m of buybacks YTD.
• Tax tailwinds: OBBBA expected to reduce 2025 cash taxes by ~ $50m via bonus depreciation and R&D expensing.

Negatives

• Review Choice Demonstration (RCD) in Alabama: hospitals did not meet validation thresholds in cycles 2 and 3; 100% pre‑claim review continues, creating collectability risk.
• Other operating expenses rose 14.2% in Q3 (provider taxes and development-related costs).
• Outpatient visits declined 21.7% YoY in Q3 (and 27.0% YTD), though outpatient is a small revenue contributor.
• Cash and cash equivalents declined to $48.7m (from $85.4m at YE 2024) amid heavy capex and capital returns.
• Noncontrolling interests increased to $48.1m in Q3 (9M: $135.9m), reducing net income attributable to common.
• Capex intensity remains high (9M $507.1m; 2025 plan $785–$820m), elevating near‑term cash needs.

Risks

• Exposure to Medicare reimbursement changes; 2026 IRF Final Rule adjustments to wage index, outliers, and case‑mix may affect hospital‑level rates.
• RCD program: Alabama IRFs failed to meet validation thresholds in cycles 2 and 3; continuing 100% pre‑claim review could delay or reduce collections.
• Potential expansion of RCD to Texas and California could increase administrative burden and reimbursement risk (48 hospitals across the four RCD states).
• Intensive regulatory oversight and audits (including statistical sampling and extrapolation) may lead to overpayment assertions and recoupments.
• Dependence on government payors (Medicare/Medicaid) and payor mix shifts could pressure pricing and profitability.
• Labor availability and retention for nurses and therapists can elevate staffing costs and constrain volumes.
• Potential qui tam (False Claims Act) litigation exposure and broader legal/regulatory proceedings.
• Information systems and data security risks affecting operations and patient data.
• Regional disruptions (e.g., severe weather in Texas/Florida) could impact volumes and facilities.
• Debt and related covenants could limit flexibility if performance weakens.
• OBBBA Medicaid-related provisions (work requirements, provider tax limits, directed payment limits) from 2027 may impact state reimbursements and referral sources.

Future Outlook

Management remains optimistic given aging demographics, improving occupancy, easing labor pressures, and a company-estimated ~2.9% Medicare rate increase effective October 1, 2025; plans call for continued de novo development and bed additions, 2025 capex of $785–$820m, and ongoing dividends and buybacks, while monitoring RCD expansion and OBBBA-related Medicaid changes beyond 2026.

Management Comments

• Confident in intermediate and long‑term prospects driven by demographic trends and the company’s scale and quality outcomes.
• Capital structure remains flexible with no significant debt maturities until 2028 and ample revolver capacity.
• Estimated the FY2026 IRF rule will yield a ~2.9% Medicare payment rate increase effective 2025-10-01.
• OBBBA tax provisions are expected to generate ~$180m of additional 2025 deductions and ~$50m in cash tax savings; estimated 2025 cash taxes of $110–$130m.
• Continuing to engage with the MAC and CMS on RCD to align reviews with Medicare coverage criteria.

Industry Context

IRFs continue to benefit from aging demographics and post‑acute demand recovery; Medicare’s FY2026 update provides a modest sector uplift while labor markets show signs of normalization. RCD expansion creates administrative and reimbursement uncertainty that could affect operators with significant exposure in RCD states. Encompass Health’s scale, owned real estate, and de novo pipeline remain competitive advantages versus regional IRF networks and hospital‑based units.

Comparison to Industry Standards

• Revenue growth of 9–11% YTD is strong relative to typical mid‑single‑digit growth seen in post‑acute providers during stable rate environments.
• Occupancy at 76.2% aligns with or slightly exceeds typical mid‑70s IRF occupancy, indicating healthy bed utilization.
• The company‑estimated ~2.9% Medicare rate lift from the FY2026 IRF rule is broadly consistent with sector expectations given the 2.6% market basket less productivity adjustment and mix effects.
• Leverage profile with no major maturities until 2028 and ample revolver capacity compares favorably to many post‑acute peers reliant on nearer‑term refinancings.
• De novo expansion pace (multiple openings and bed additions in 2025) exceeds most hospital‑based IRF competitors and is comparable to leading dedicated IRF platforms.

Legal Proceedings

• Subject to ongoing regulatory audits, investigations, and litigation typical for healthcare providers; potential exposure to sealed and future False Claims Act qui tam actions.

Stakeholder Impact

• Shareholders benefit from dividend increase to $0.19 and ongoing buybacks; long‑term growth supported by de novos.
• Employees see continued hiring and reduced reliance on contract labor amid expansion.
• Patients gain access through new hospitals and added beds, supporting higher occupancy and capacity.
• Creditors’ position supported by strong operating cash flow and redemption of 2025 notes; no major maturities until 2028.
• Payors and regulators affected by RCD and IRF rate updates; company engagement may influence claim processing outcomes.

Next Steps

• Continue pre‑claim submissions under RCD in Alabama and engage with MAC/CMS to resolve non‑affirmation issues.
• Execute 2025 capex plan ($785–$820m) including de novos, satellites, and bed additions; complete ~$424m of projects under construction over the next two years.
• Implement FY2026 IRF rate changes effective 2025-10-01 and monitor hospital‑level impacts.
• Maintain shareholder returns via dividends ($0.19 per share) and remaining $408m buyback authorization.
• Evaluate and capture cash tax savings from OBBBA provisions; monitor 2027+ Medicaid policy impacts.

Key Dates

Recommendation

The report shows healthy revenue and earnings growth, improving occupancy, easing labor headwinds, strong Adjusted EBITDA, and robust operating cash flow. Balance sheet flexibility, no significant maturities until 2028, and a visible de novo pipeline support continued expansion. While RCD poses reimbursement risk, the expected ~2.9% Medicare rate increase and OBBBA tax savings provide near‑term offsets. On balance, the fundamentals justify a constructive view.

Keywords

Encompass Health, inpatient rehabilitation, IRF, Medicare, RCD, Adjusted EBITDA, discharges, occupancy, capex, dividend, share repurchase, OBBBA, rate update, revolving credit facility, noncontrolling interests